Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Added to Semaglutide and Diet in Obesity and Type 2 Diabetes
NCT07599046Not yet recruiting
- Sponsor
- Eighth Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of Fecal Microbiota Transplantation Capsule in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eighth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Percent change in body weight at 24 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07599046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599046.